ES2149226T3 - Antagonistas de angiotensina ii como farmaco profilactico o terapeutico para enfermedades renales. - Google Patents

Antagonistas de angiotensina ii como farmaco profilactico o terapeutico para enfermedades renales.

Info

Publication number
ES2149226T3
ES2149226T3 ES94106203T ES94106203T ES2149226T3 ES 2149226 T3 ES2149226 T3 ES 2149226T3 ES 94106203 T ES94106203 T ES 94106203T ES 94106203 T ES94106203 T ES 94106203T ES 2149226 T3 ES2149226 T3 ES 2149226T3
Authority
ES
Spain
Prior art keywords
stands
therapeutic drug
prophylatic
angiotensin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106203T
Other languages
English (en)
Inventor
Kohei Nishikawa
Yumiko Shibouta
Keiji Kubo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2149226T3 publication Critical patent/ES2149226T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA MEDICINA PROFILACTICA O TERAPEUTICA PARA NEFROPATIA DIABETICA O GLOMERULONEFRITIS, COMPRENDIENDO, COMO INGREDIENTE ACTIVO, UN COMPUESTO O SAL DEL MISMO REPRESENTADO POR LA FORMULA GENERAL (I), EN LA QUE: R1 REPRESENTA H O UN RESIDUO DE HIDROCARBURO OPCIONALMENTE SUSTITUIDO; R2 REPRESENTA UN GRUPO CARBOXILO OPCIONALMENTE ESTERIFICADO; R3 REPRESENTA UN GRUPO REAL O POTENCIALMENTE CAPAZ DE FORMAR UN ANION; X MUESTRA QUE LOS GRUPOS FENILENO Y FENIL SE ENLAZAN MUTUAMENTE, BIEN DIRECTAMENTE BIEN A TRAVES DE UN SEPARADOR QUE TIENE UNA LONGITUD DE CADENA ATOMICA DE DOS O MENOS; N REPRESENTA 1 O 2; EL ANILLO A REPRESENTA UN ANILLO DE BENCENO, QUE TIENE UN SUBSTITUYENTE OPCIONAL EN ADICION A R2; Y REPRESENTA UN ENLACE, TE SUSTITUIDO).
ES94106203T 1993-04-22 1994-04-21 Antagonistas de angiotensina ii como farmaco profilactico o terapeutico para enfermedades renales. Expired - Lifetime ES2149226T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9594293 1993-04-22

Publications (1)

Publication Number Publication Date
ES2149226T3 true ES2149226T3 (es) 2000-11-01

Family

ID=14151326

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106203T Expired - Lifetime ES2149226T3 (es) 1993-04-22 1994-04-21 Antagonistas de angiotensina ii como farmaco profilactico o terapeutico para enfermedades renales.

Country Status (12)

Country Link
US (7) US5719173A (es)
EP (1) EP0622077B1 (es)
JP (1) JP3810020B2 (es)
AT (1) ATE194284T1 (es)
BR (1) BR1100756KB1 (es)
CA (1) CA2121871C (es)
CY (1) CY2204B1 (es)
DE (1) DE69425085T2 (es)
DK (1) DK0622077T3 (es)
ES (1) ES2149226T3 (es)
GR (1) GR3033862T3 (es)
PT (1) PT622077E (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
JP2003306432A (ja) * 1993-04-22 2003-10-28 Takeda Chem Ind Ltd 腎疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
EP0760316B1 (en) * 1995-02-10 2004-03-17 Enshu Co., Ltd. Seat belt suspender
EP0843559A2 (en) * 1996-06-11 1998-05-27 Zonagen, Inc. Chitosan drug delivery system
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
CA2400124C (en) * 2000-02-18 2010-12-14 Kazuaki Ikeya Tnf-.alpha. inhibitors
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
WO2004071534A1 (ja) * 2003-02-17 2004-08-26 Takeda Pharmaceutical Company Limited 腎疾患の予防・治療剤
US7021099B2 (en) * 2003-06-12 2006-04-04 General Motors Corporation Extraction system for hot formed parts
CA2547785A1 (en) * 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2006046528A1 (ja) * 2004-10-29 2006-05-04 Kowa Co., Ltd. 糸球体疾患治療剤
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US9066936B2 (en) * 2007-03-28 2015-06-30 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
JP5559696B2 (ja) * 2008-10-22 2014-07-23 協和発酵キリン株式会社 糖尿病性腎症の治療剤
CA2802414C (en) 2010-06-17 2018-01-09 Nitto Denko Corporation Agent for treating renal fibrosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128256A (en) * 1987-01-12 1992-07-07 Stratagene DNA cloning vectors with in vivo excisable plasmids
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
DE69013607T2 (de) * 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
DE3927170A1 (de) * 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
US5162326A (en) * 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
US5284661A (en) * 1990-02-22 1994-02-08 Takeda Chemical Industries, Ltd. Fused thiophene derivatives, their production and use
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
ES2121773T3 (es) * 1990-06-08 1998-12-16 Hoechst Marion Roussel Inc Derivados de bencimidazol, su procedimiento de preparacion, productos intermedios, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
JPH05509086A (ja) * 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
AU8405691A (en) * 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
AU636066B2 (en) * 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
TW274551B (es) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
EP0588299B1 (en) * 1992-09-14 1998-07-01 Takeda Chemical Industries, Ltd. 1,2,4-Oxadiazolyl- or 1,2,4-thiadiazolyl-biphenyl derivatives as angiotensin II antagonists
EP0603712B1 (en) * 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤

Also Published As

Publication number Publication date
DK0622077T3 (da) 2000-10-23
US6686383B2 (en) 2004-02-03
US20030114509A1 (en) 2003-06-19
CY2204B1 (en) 2002-11-08
EP0622077A1 (en) 1994-11-02
EP0622077B1 (en) 2000-07-05
GR3033862T3 (en) 2000-10-31
JPH072667A (ja) 1995-01-06
JP3810020B2 (ja) 2006-08-16
US6040324A (en) 2000-03-21
US6319938B1 (en) 2001-11-20
US20040082636A1 (en) 2004-04-29
ATE194284T1 (de) 2000-07-15
DE69425085D1 (de) 2000-08-10
US20020045652A1 (en) 2002-04-18
CA2121871A1 (en) 1994-10-23
PT622077E (pt) 2000-10-31
DE69425085T2 (de) 2000-11-09
CA2121871C (en) 2006-12-12
BR1100756KB1 (pt) 2011-10-18
US5889036A (en) 1999-03-30
US6469037B2 (en) 2002-10-22
US5719173A (en) 1998-02-17
US7135490B2 (en) 2006-11-14

Similar Documents

Publication Publication Date Title
ES2149226T3 (es) Antagonistas de angiotensina ii como farmaco profilactico o terapeutico para enfermedades renales.
ATE253546T1 (de) Chalcon-derivate und medikamente die diese enthalten
SG45336A1 (en) A pharmaceutical composition for angiotens ii-mediated diseases
NO955256L (no) Fenylheterosykluser som syklooksygenase-2-inhibitorer
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
ATE433971T1 (de) Neue azolderivate
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
DE69709493D1 (de) Substituierte Indazolderivate
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
EP1329218A4 (en) PREVENTIVE / REMEDY AGENTS FOR PORTAL HYPERTENSION
ATE386716T1 (de) Biphenylderivate
DE60202575D1 (de) 3,4-Dihydro-1H-Naphthalin-Derivate als hoch selektive Cyclooxygenase-2-Inhibitoren
TH41374A (th) สารประกอบทางเภสัชกรรมประเภทใหม่
TH17299A (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 622077

Country of ref document: ES